Información de Novartis AG, dividendo de Novartis AG, actividades de los accionistas y más

Más Datos de Novartis AG Compañía

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Información de Novartis AG



Símbolo de cotizaciónNVS

Nombre de la empresaNovartis AG

Fecha de salida a bolsaMay 07, 2001

Director ejecutivoNarasimhan (Vasant)

Número de empleados75883

Tipo de seguridadDepository Receipt

Fin del año fiscalMay 07

DirecciónLichtstrasse 35

CiudadBASEL

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísSwitzerland

Código postal4056

Teléfono41613241111

Sitio Webhttps://www.novartis.com/

Símbolo de cotizaciónNVS

Fecha de salida a bolsaMay 07, 2001

Director ejecutivoNarasimhan (Vasant)

Ejecutivos de Novartis AG



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

--

Ms. Charlotte Pamer- Wieser, Ph.D.

Corporate Secretary

--

Dr. Nancy C. Andrews, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Ton Buechner

Non-Executive Independent Director

--

Ms. Elizabeth (Liz) Doherty

Non-Executive Independent Director

--

Dr. Vasant (Vas) Narasimhan, M.D.

Chief Executive Officer, Member of the Executive Committee

--

Mr. Frans van Houten

Non-Executive Independent Director

--

Dr. Steffen Lang, Ph.D.

President - Operations, Member of the Executive Committee

--

Mr. Patrice Bula

Non-Executive Lead Independent Director

--

Ms. Bridgette P. Heller

Non-Executive Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

--

Ms. Charlotte Pamer- Wieser, Ph.D.

Corporate Secretary

--

Dr. Nancy C. Andrews, M.D., Ph.D.

Non-Executive Independent Director

--

Mr. Ton Buechner

Non-Executive Independent Director

--

Ms. Elizabeth (Liz) Doherty

Non-Executive Independent Director

--

Dr. Vasant (Vas) Narasimhan, M.D.

Chief Executive Officer, Member of the Executive Committee

--

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Rest of portfolio

2.56B

18.40%

Cardiovascular, Renal and Metabolism - Entresto

1.88B

13.49%

Immunology - Cosentyx

1.70B

12.21%

Oncology -Kisqali

1.33B

9.55%

Neuroscience - Kesimpta

1.22B

8.79%

Otro

5.22B

37.56%

Por regiónUSD

Nombre

Ganancia

Proporción

US

6.04B

43.40%

Europe

4.25B

30.56%

Asia / Africa / Australasia

2.67B

19.17%

Canada and Latin America

956.00M

6.87%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Rest of portfolio

2.56B

18.40%

Cardiovascular, Renal and Metabolism - Entresto

1.88B

13.49%

Immunology - Cosentyx

1.70B

12.21%

Oncology -Kisqali

1.33B

9.55%

Neuroscience - Kesimpta

1.22B

8.79%

Otro

5.22B

37.56%

Estadísticas de accionistas

Actualizado: dom., 1 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

Dodge & Cox

0.55%

PRIMECAP Management Company

0.49%

Dimensional Fund Advisors, L.P.

0.46%

Fisher Investments

0.38%

Loomis, Sayles & Company, L.P.

0.30%

Otro

97.83%

Accionistas

Proporción

Dodge & Cox

0.55%

PRIMECAP Management Company

0.49%

Dimensional Fund Advisors, L.P.

0.46%

Fisher Investments

0.38%

Loomis, Sayles & Company, L.P.

0.30%

Otro

97.83%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

3.37%

Investment Advisor/Hedge Fund

2.86%

Research Firm

0.48%

Hedge Fund

0.20%

Bank and Trust

0.13%

Pension Fund

0.03%

Family Office

0.02%

Otro

92.91%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

2023

135.99M

7.08%

-9.78M

2025Q3

1967

135.58M

7.06%

-11.39M

2025Q2

1941

140.71M

7.27%

+2.13M

2025Q1

1953

141.07M

7.20%

+870.45K

2024Q4

1926

134.00M

6.78%

-9.24M

2024Q3

1858

134.89M

6.74%

-11.71M

2024Q2

1840

139.20M

6.87%

-9.16M

2024Q1

1808

141.30M

6.92%

-7.93M

2023Q4

1811

141.99M

6.94%

-15.97M

2023Q3

1775

150.92M

7.33%

-7.18M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Dodge & Cox

10.59M

0.55%

-62.48K

-0.59%

Sep 30, 2025

PRIMECAP Management Company

9.34M

0.49%

-1.06M

-10.19%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

8.84M

0.46%

-220.21K

-2.43%

Sep 30, 2025

Fisher Investments

7.24M

0.38%

+117.95K

+1.66%

Sep 30, 2025

Loomis, Sayles & Company, L.P.

5.66M

0.3%

+83.33K

+1.49%

Sep 30, 2025

Franklin Mutual Advisers, LLC

3.98M

0.21%

-184.68K

-4.44%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

3.68M

0.19%

+29.41K

+0.81%

Sep 30, 2025

Parametric Portfolio Associates LLC

3.19M

0.17%

+113.80K

+3.70%

Sep 30, 2025

Managed Account Advisors LLC

3.04M

0.16%

+120.48K

+4.13%

Sep 30, 2025

Aperio Group, LLC

2.45M

0.13%

+205.41K

+9.16%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

VanEck Pharmaceutical ETF

19.83%

Amplify International Enhanced Dividend Income ETF

3.67%

Abacus FCF International Leaders ETF

3.41%

Altrius Global Dividend ETF

2.39%

Invesco International Dividend Achievers ETF

2.08%

Freedom Day Dividend ETF

2.03%

Fundamentals First ETF

1.91%

SP Funds S&P World (ex-US) ETF

1.56%

DFA Dimensional Internatl High Profitability ETF

1.54%

Avantis Responsible International Equity ETF

1.35%

VanEck Pharmaceutical ETF

Proporción19.83%

Amplify International Enhanced Dividend Income ETF

Proporción3.67%

Abacus FCF International Leaders ETF

Proporción3.41%

Altrius Global Dividend ETF

Proporción2.39%

Invesco International Dividend Achievers ETF

Proporción2.08%

Freedom Day Dividend ETF

Proporción2.03%

Fundamentals First ETF

Proporción1.91%

SP Funds S&P World (ex-US) ETF

Proporción1.56%

DFA Dimensional Internatl High Profitability ETF

Proporción1.54%

Avantis Responsible International Equity ETF

Proporción1.35%

Dividendos



Un total de 29.75B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Feb 20, 2025

NVS.NB Final Cash Dividend of gross USD 3.99399 paid on Apr 25, 2025 going ex on Mar 12, 2025

Mar 12, 2025

Apr 25, 2025

Mar 12, 2025

Feb 12, 2024

NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024

Mar 08, 2024

Apr 19, 2024

Mar 07, 2024

Feb 02, 2023

NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023

Mar 10, 2023

Mar 20, 2023

Mar 09, 2023

Feb 04, 2022

NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022

Mar 09, 2022

Mar 17, 2022

Mar 08, 2022

Jan 26, 2021

NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021

Mar 05, 2021

Mar 15, 2021

Mar 04, 2021

Jan 31, 2020

NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020

Mar 04, 2020

Mar 12, 2020

Mar 03, 2020

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos